知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.027 秒)

    BETA-ADRENERGIC RECEPTOR AGONISTS AND USES THEREOF
    1.
    发明申请
    BETA-ADRENERGIC RECEPTOR AGONISTS AND USES THEREOF 审中-公开
    β-ADRENERGIC RECEPTOR AGONISTS及其用途

    公开(公告)号：US20120329879A1

    公开(公告)日：2012-12-27

    申请号：US13607216

    申请日：2012-09-07

    申请人： Jena J. Steinle ,  Kimberly P. Williams ,  Jayaprakash Pagadala ,  Duane D. Miller

    发明人： Jena J. Steinle ,  Kimberly P. Williams ,  Jayaprakash Pagadala ,  Duane D. Miller

    IPC分类号： A61K31/137 ,  C07C215/56 ,  C12N5/071 ,  A61P27/02

    CPC分类号： A61K31/137

    摘要： Provided herein are methods for improving function in a retinal cell associated with a diabetic condition and for treating a diabetic retinopathic condition in a subject. The methods comprise contacting the retinal cell or administering to the subject a beta-adrenergic receptor agonist or R-isomer thereof such as have the chemical structural formula: where R1 is (CH2)n(CH3)2 or where n is 1 to 4, R2 is H or H.HX, where X is a halide and R3 is O(CH2)mCH3 at one or more of C2-C6, where m is 0 to 4. Also provided are BAR agonists having the structural where R1 is the (CH2)n-phenyl-R2 substituent and the hydroxy-benzene moiety is 1,2-benzene diol or 1,3-benzene diol.

    摘要翻译： 本文提供了用于改善与糖尿病状况相关的视网膜细胞的功能和用于治疗受试者的糖尿病视网膜病变症状的方法。 所述方法包括使视网膜细胞接触或向受试者施用β-肾上腺素能受体激动剂或其R-异构体，例如具有以下化学结构式：其中R 1为（CH 2）n（CH 3）2或n为1至4， R2是H或H.HX，其中X是卤素，R3是一个或多个C2-C6上的O（CH2）mCH3，其中m是0-4。还提供了具有结构的BAR激动剂，其中R1是（ CH2）n-苯基-R2取代基，羟基 - 苯部分是1,2-苯二醇或1,3-苯二醇。

    N-OXIDES OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AS PRODRUGS
    2.
    发明申请
    N-OXIDES OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AS PRODRUGS 有权
    芬太尼氧化物和邻苯二甲酸氧氟沙星作为PRODRUGS

    公开(公告)号：US20090005455A1

    公开(公告)日：2009-01-01

    申请号：US12143919

    申请日：2008-06-23

    申请人： Lechoslaw A. Turski ,  Axel Stoit ,  Cornelis G. Kruse ,  Sander Vader ,  Martinus Th.M. Tulp

    发明人： Lechoslaw A. Turski ,  Axel Stoit ,  Cornelis G. Kruse ,  Sander Vader ,  Martinus Th.M. Tulp

    IPC分类号： A61K31/135 ,  C07C217/74 ,  A61P25/00 ,  C07C215/56

    CPC分类号： C07C291/04

    摘要： Embodiments of the invention relate to a compound of formula (1), or a tautomer, stereoisomer, hydrate, or solvate thereof, wherein R1 is H or CH3. Other embodiments of the invention relate to a pharmaceutical composition containing these compound, to methods for preparing these compounds, and to methods for preparing compositions containing these compounds. Yet other embodiments of the invention relate to the uses of these compounds and compositions containing it, such as for the manufacture of medicaments and pharmaceutical compositions for treating a condition chosen from depression, major depressive disorder, generalized anxiety disorder, obsessive compulsive disorder, social anxiety disorder, panic disorder, general depressive disorders, diabetic neuropathy, migraine and hot flashes.

    摘要翻译： 本发明的实施方案涉及式（1）的化合物或其互变异构体，立体异构体，水合物或溶剂合物，其中R 1为H或CH 3。 本发明的其它实施方案涉及含有这些化合物的药物组合物，制备这些化合物的方法以及制备含有这些化合物的组合物的方法。 本发明的其它实施方案涉及这些化合物和含有它们的组合物的用途，例如用于制备用于治疗选自抑郁症，重度抑郁障碍，广泛性焦虑症，强迫症，社会焦虑症的药物和药物组合物 障碍，恐慌症，一般抑郁障碍，糖尿病性神经病，偏头痛和潮热。

    Tolterodine salts
    3.
    发明申请
    Tolterodine salts 失效
    托特罗定盐

    公开(公告)号：US20030199582A1

    公开(公告)日：2003-10-23

    申请号：US10127875

    申请日：2002-04-23

    发明人： Michael Hawley ,  Satish Kumar Singh ,  Walter Morozowich ,  Mark P. Warchol

    IPC分类号： A61K031/205 ,  C07C215/56

    CPC分类号： A61K31/205 ,  C07C215/54

    摘要： The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, the compounds for use as medicaments, and use of the compounds for the manufacture of specific medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are pharmaceutically acceptable salts of tolterodine or hydroxytolterodine, wherein the salt is of an acid selected from the group consisting of aliphatic mono- and dicarboxylic acids comprising from 7 to 24 carbon atoms, alkanedisulfonic acids comprising from 2 to 4 carbon atoms, naphthoic acid derivatives comprising from 11 to 27 carbon atoms, maleic acid and fumaric acid.

    摘要翻译： 本发明涉及新型药物活性化合物，含有它们的药物组合物，用作药物的化合物以及该化合物用于制备特定药物的用途。 本发明还涉及涉及给药化合物的治疗方法。 具体地说，这些化合物是托特罗定或羟基炔诺酮的药学上可接受的盐，其中该盐是选自包含7-24个碳原子的脂族单羧酸和二羧酸，包含2至4个碳原子的链烷二磺酸， 包含11至27个碳原子的萘甲酸衍生物，马来酸和富马酸。